Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Fineline Cube Apr 28, 2026
Company

Ping An Good Doctor Launches AI-Powered Digital Doctor Service

Fineline Cube Feb 27, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...

Company

Eli Lilly to Establish Four New US Pharma Manufacturing Sites

Fineline Cube Feb 27, 2025

US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical...

Company Drug

Precigen’s RRP Therapy PRGN-2012 Gets FDA Review

Fineline Cube Feb 27, 2025

US-based cell and gene therapy (CGT) specialist Precigen, Inc. (NASDAQ: PGEN) announced that the US...

Company Deals

Burning Rock and MGI Tech Partner to Advance Oncology Precision Medicine

Fineline Cube Feb 27, 2025

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has entered into a strategic partnership with...

Company Deals

Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field

Fineline Cube Feb 27, 2025

Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract...

Company Drug

InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum

Fineline Cube Feb 27, 2025

Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...

Company Drug

Jiangsu Hengrui’s HRS-1301 Receives NMPA Approval for Hyperlipidemia

Fineline Cube Feb 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its Category 1 chemical drug...

Company Drug

Hepalink Pharmaceutical’s Enoparin Receives Argentina Approval for Thromboembolic Diseases

Fineline Cube Feb 27, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that its subsidiary, Shenzhen Techdow...

Company Medical Device

Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment

Fineline Cube Feb 27, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced that its subsidiary, Shanghai Angiocare...

Company Drug

Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients

Fineline Cube Feb 27, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received...

Company Deals

WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development

Fineline Cube Feb 26, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Kexing Biopharm and Bio-Sincerity Pharmaceutical Form Strategic Alliance

Fineline Cube Feb 26, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) and Hangzhou Bio-Sincerity Pharmaceutical Technology Co., Ltd. (SHE:...

Company Deals

Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy

Fineline Cube Feb 26, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed...

Company Deals Hospital

Basecare and Rhea Labs Form Five-Year Alliance to Expand IVF Markets Globally

Fineline Cube Feb 26, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has entered into a five-year...

Company Deals

Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates

Fineline Cube Feb 26, 2025

Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences,...

Company Deals

Hansoh Pharmaceutical’s HS-10561 Receives NMPA Clearance for Chronic Spontaneous Urticaria

Fineline Cube Feb 26, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received clinical trial...

Company Medical Device

J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China

Fineline Cube Feb 26, 2025

Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC...

Company Deals

Thermo Fisher to Acquire Solventum’s Purification Business for USD 4.1B

Fineline Cube Feb 26, 2025

Thermo Fisher Scientific (NYSE: TMO) has agreed to acquire Solventum’s (NYSE: SOLV) Purification & Filtration...

Company Drug

J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment

Fineline Cube Feb 26, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...

Company Drug

Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy

Fineline Cube Feb 26, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...

Posts pagination

1 … 197 198 199 … 657

Recent updates

  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
  • Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
  • Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Others

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.